Travere Therapeutics reported a quarterly loss of $0.39 per share, wider than the Zacks Consensus Estimate for a $0.30 loss. The result was still an improvement from a $0.47 loss per share a year ago, but the miss versus expectations is a modest negative for the stock.
Travere Therapeutics reported a quarterly loss of $0.39 per share, wider than the Zacks Consensus Estimate for a $0.30 loss. The result was still an improvement from a $0.47 loss per share a year ago, but the miss versus expectations is a modest negative for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.18
Ticker Sentiment
